Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Issue 1 (18th December 2020)

• Record Type: Journal Article
• Authors: Hansson, Oskar; Rutz, Sandra; Zetterberg, Henrik; Bauer, Ekaterina; Hähl, Teresa; Manuilova, Ekaterina; Mert, Mehmet Can; Wahl, Simone; Blennow, Kaj; Stomrud, Erik
• Is Part Of: Alzheimer's & dementia. Volume 12:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-18
• Subjects: Alzheimer's disease -- amyloid beta -- biomarker -- cerebrospinal fluid -- diagnosis -- pre‐analytical -- tau; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1002/dad2.12137
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Introduction: We aimed to establish a standardized, routine‐use pre‐analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre‐analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low‐bind false‐bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)1‐42 levels varied by tube type, using a low‐bind FBT reduced variation. Aβ1‐42 levels were higher with no mixing versus roller/inversion mixing. Aβ1‐42 levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ1‐40 levels were less strongly affected. Phospho‐tau and total‐tau levels were largely unaffected. Discussion: We propose an easy‐to‐use, standardized, routine‐use pre‐analytical protocol, using low‐bind FBTs, for measuring AD CSF biomarkers in clinical practice.